Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
3.350
+0.050 (1.52%)
At close: Dec 27, 2024, 4:00 PM
3.360
+0.010 (0.30%)
After-hours: Dec 27, 2024, 7:52 PM EST
Geron Revenue
Geron had revenue of $28.27M in the quarter ending September 30, 2024, with 17,138.41% growth. This brings the company's revenue in the last twelve months to $29.48M, up 9,199.68% year-over-year. In the year 2023, Geron had annual revenue of $237.00K, down -60.23%.
Revenue (ttm)
$29.48M
Revenue Growth
+9,199.68%
P/S Ratio
71.45
Revenue / Employee
$209,078
Employees
141
Market Cap
2.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 237.00K | -359.00K | -60.23% |
| Dec 31, 2022 | 596.00K | -797.00K | -57.21% |
| Dec 31, 2021 | 1.39M | 1.14M | 450.59% |
| Dec 31, 2020 | 253.00K | -207.00K | -45.00% |
| Dec 31, 2019 | 460.00K | -606.00K | -56.85% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PACS Group | 3.56B |
| Alignment Healthcare | 2.47B |
| Omnicell | 1.06B |
| Harmony Biosciences Holdings | 681.88M |
| Supernus Pharmaceuticals | 651.97M |
| Mirum Pharmaceuticals | 307.03M |
| Tarsus Pharmaceuticals | 129.62M |
| Wave Life Sciences | 53.61M |
GERN News
- 8 days ago - Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 14 days ago - Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS - Business Wire
- 17 days ago - Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies - Business Wire
- 17 days ago - Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis - Business Wire
- 4 weeks ago - Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 5 weeks ago - Geron: A Strong Launch And Financial Deals Make It Attractive - Seeking Alpha
- 6 weeks ago - Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development - Business Wire
- 6 weeks ago - Geron to Participate in the Stifel 2024 Healthcare Conference - Business Wire